Ann Anat:谷氨酸诱导大鼠视网膜神经元的调节性坏死

2018-09-27 MedSci MedSci原创

中南大学基础医学院解剖与神经生物学系的Wang S和Huang Y近日在Ann Anat发表了一篇文章,他们研究的目的是探究钙蛋白酶抑制剂(CAST)是否在过量谷氨酸条件下对大鼠视网膜神经元中的调节性坏死(RN)过程中起作用,并进一步研究该过程是否受calapin1和钙蛋白酶2调节

中南大学基础医学院解剖与神经生物学系的Wang S和Huang Y近日在Ann Anat发表了一篇文章,他们研究的目的是探究钙蛋白酶抑制剂(CAST)是否在过量谷氨酸条件下对大鼠视网膜神经元中的调节性坏死(RN)过程中起作用,并进一步研究该过程是否受calapin1和钙蛋白酶2调节。

在本研究中,在损伤后谷氨酸盐触发CAST抑制、钙蛋白酶2激活和视网膜神经元调节性坏死。CAST活性肽可以激活钙蛋白酶2,并对其介导的RN提供保护作用。然而,这些过程中calpain1活性没有改变。最后,体内研究进一步证实,谷氨酸激发大鼠视网膜神经节细胞层和内核层中CAST-calpain2通路,并在细胞RN过程中发挥重要的作用。此外,视网膜电图结果表明,使用CAST肽处理后可恢复谷氨酸诱导的视功能受损。

因此,他们认为,该研究表明,过量的谷氨酸可能导致CAST抑制,并激活钙蛋白酶2,但不会引起钙蛋白酶1激活,最终引起视网膜神经元中的调节性坏死(RN)。

原文出处:

Wang, S., et al., Calpain2 but not Calpain1 Mediated by Calpastatin Following Glutamate-Induced Regulated Necrosis in Rat Retinal Neurons. Ann Anat, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1801572, encodeId=30a318015e265, content=<a href='/topic/show?id=9cd690e860a' target=_blank style='color:#2F92EE;'>#视网膜神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90786, encryptionId=9cd690e860a, topicName=视网膜神经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Jul 31 07:47:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633491, encodeId=205f16334916a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 16 22:47:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883330, encodeId=5fa1188333055, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 22 14:47:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270114, encodeId=fb0a12e0114c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362908, encodeId=3ae91362908e3, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347076, encodeId=329434e076fc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Sep 28 07:55:28 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346987, encodeId=62a734698eac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Sep 27 22:36:37 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1801572, encodeId=30a318015e265, content=<a href='/topic/show?id=9cd690e860a' target=_blank style='color:#2F92EE;'>#视网膜神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90786, encryptionId=9cd690e860a, topicName=视网膜神经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Jul 31 07:47:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633491, encodeId=205f16334916a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 16 22:47:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883330, encodeId=5fa1188333055, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 22 14:47:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270114, encodeId=fb0a12e0114c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362908, encodeId=3ae91362908e3, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347076, encodeId=329434e076fc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Sep 28 07:55:28 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346987, encodeId=62a734698eac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Sep 27 22:36:37 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2019-01-16 AspirantSuo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1801572, encodeId=30a318015e265, content=<a href='/topic/show?id=9cd690e860a' target=_blank style='color:#2F92EE;'>#视网膜神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90786, encryptionId=9cd690e860a, topicName=视网膜神经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Jul 31 07:47:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633491, encodeId=205f16334916a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 16 22:47:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883330, encodeId=5fa1188333055, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 22 14:47:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270114, encodeId=fb0a12e0114c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362908, encodeId=3ae91362908e3, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347076, encodeId=329434e076fc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Sep 28 07:55:28 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346987, encodeId=62a734698eac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Sep 27 22:36:37 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2019-02-22 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1801572, encodeId=30a318015e265, content=<a href='/topic/show?id=9cd690e860a' target=_blank style='color:#2F92EE;'>#视网膜神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90786, encryptionId=9cd690e860a, topicName=视网膜神经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Jul 31 07:47:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633491, encodeId=205f16334916a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 16 22:47:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883330, encodeId=5fa1188333055, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 22 14:47:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270114, encodeId=fb0a12e0114c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362908, encodeId=3ae91362908e3, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347076, encodeId=329434e076fc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Sep 28 07:55:28 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346987, encodeId=62a734698eac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Sep 27 22:36:37 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2018-09-29 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1801572, encodeId=30a318015e265, content=<a href='/topic/show?id=9cd690e860a' target=_blank style='color:#2F92EE;'>#视网膜神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90786, encryptionId=9cd690e860a, topicName=视网膜神经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Jul 31 07:47:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633491, encodeId=205f16334916a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 16 22:47:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883330, encodeId=5fa1188333055, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 22 14:47:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270114, encodeId=fb0a12e0114c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362908, encodeId=3ae91362908e3, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347076, encodeId=329434e076fc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Sep 28 07:55:28 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346987, encodeId=62a734698eac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Sep 27 22:36:37 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2018-09-29 millore
  6. [GetPortalCommentsPageByObjectIdResponse(id=1801572, encodeId=30a318015e265, content=<a href='/topic/show?id=9cd690e860a' target=_blank style='color:#2F92EE;'>#视网膜神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90786, encryptionId=9cd690e860a, topicName=视网膜神经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Jul 31 07:47:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633491, encodeId=205f16334916a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 16 22:47:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883330, encodeId=5fa1188333055, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 22 14:47:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270114, encodeId=fb0a12e0114c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362908, encodeId=3ae91362908e3, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347076, encodeId=329434e076fc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Sep 28 07:55:28 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346987, encodeId=62a734698eac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Sep 27 22:36:37 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2018-09-28 orangesking

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1801572, encodeId=30a318015e265, content=<a href='/topic/show?id=9cd690e860a' target=_blank style='color:#2F92EE;'>#视网膜神经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90786, encryptionId=9cd690e860a, topicName=视网膜神经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Wed Jul 31 07:47:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633491, encodeId=205f16334916a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 16 22:47:00 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883330, encodeId=5fa1188333055, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 22 14:47:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270114, encodeId=fb0a12e0114c3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362908, encodeId=3ae91362908e3, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sat Sep 29 12:47:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347076, encodeId=329434e076fc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Sep 28 07:55:28 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346987, encodeId=62a734698eac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Sep 27 22:36:37 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2018-09-27 医者仁心5538

    学习了

    0

相关资讯

JAMA:胰岛自身抗体血清转化或为1型糖尿病预测因子

对于具有1型糖尿病较高遗传学风险的儿童而言,外周血中出现循环多重胰岛自身抗体预示着很可能进展为1型糖尿病,而且就发生在未 来的数年间。这一汇总分析报告发表于《美国医学会杂志》6月19日一期中(JAMA 2013;309:2473-9)。 德国慕尼黑理工大学糖尿病研究院的Anette G. Ziegler博士及其同事称,这一研究意味着高危儿童在出现血清转化时便进入了1型糖尿病临床前阶段。在发生血清

Biol Psychiat:颠覆性发现:精神疾病早期的大脑异常信号

发表在Biological Psychiatry上的一项最新研究发现,经历第一次精神疾病的年轻人,其大脑中谷氨酸和甘氨酸水平升高,这是精神障碍患者甘氨酸水平的首次测量。

J Neurosci:提振谷氨酸受体恢复FTD小鼠的突触功能

根据发表在Journal of Neuroscience杂志的一项研究证实:一种提提振特定类型神经递质受体功能的药物可以给老年痴呆症患者的第二个最常见类型(额颞叶痴呆症)提供治疗效益。 额颞叶痴呆症被称为FTD,是一种破坏性的疾病,其中患者有行为,个性和社会技能的巨大变化。FTD发病年龄是相对年轻的,发病年龄是在50岁末左右。患者预后严峻,病情会迅速恶化,通常在发病后10年内死亡。目前,还没

Circulation:肺动脉高压的新机制!

在肺动脉高压(PAH)中,肺血管细胞的过度增殖和凋亡抵抗性是血管重构的重要方面。目前,有一些特定的PAH治疗方法,主要针对内皮功能障碍,但过高的肺动脉压仍然会导致心力衰竭和死亡。肺血管重塑可能由血管细胞的代谢重编程驱动,以增加谷氨酰胺分解和谷氨酸生产。N-甲基-D-天冬氨酸受体(NMDAR)是主要的神经元谷氨酸受体,其也在血管细胞上表达,但其在PAH中的作用未知。近期,一项发表在杂志Circula

APNM:锻炼可降低大脑中过量谷氨酸的毒性作用

最近,一项发表于国际杂志Applied Physiology,Nutrition,and Metabolism上的研究论文中,来自圭尔夫大学(university of guelph)的研究人员通过研究发现,锻炼或许可以潜在降低大脑中谷氨酸的毒性积累,同时还可以降低多种大脑障碍疾病的严重型,比如亨廷顿病等。